Liver Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Liver Cancer Information Center has current, evidence-based information for you. Get the facts about liver cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing liver cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Liver Community is the leading Social Media Application for Liver patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
The breakthrough from this study is that most enhanced recovery studies stop measuring their outcome at length of hospital stay Infection with Hepatitis C Increases Risk of Cirrhosis
Risk of liver disease starts soon after infection OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine
Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition...
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Men, Fertility, and Cancer
Men who confront a cancer diagnosis before beginning or completing their families...
Liver Cancer Management
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer... Pay it Forward
Survivors become peer mentors to newly diagnosed women and offer experience, insight,...
Liver Cancer Clinical Trials
COGAEPI04C1 – Low Birth Weight & Other Risk Factors for Hepatoblastoma- A Groupwide Protocol
INSTOX-05-024 – Phase II Trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) in the Treatment of Hepatocellular Carcinoma (HCC) in patients with adequate platelets (>100,000/?L)
ZX101-301 – A Phase II Randomized Controlled Study Comparing The Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ To Patients Treated With Doxorubicin